EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan

Daisuke Kotani, Takayuki Yoshino, Toshiki Masuishi, Yu Sunakawa, Atsuo Takashima, Kentaro Yamazaki, Hisato Kawakami, Tomohiro Nishina, Yoshito Komatsu, Taito Esaki, Cathy Eng, Stacey Ukrainskyj und 6 weitere

International Journal of Clinical Oncology · 2025

DOI: 10.1007/s10147-025-02852-9 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Daisuke Kotani und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. dkotani@east.ncc.go.jp. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Benzofurans, Quinazolines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HUTCHMED.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the phase 3 FRESCO-2 study, fruquintinib plus best supportive care (BSC) significantly improved overall survival (OS) versus placebo plus BSC in patients with refractory metastatic colorectal cancer (mCRC). We present the results of a FRESCO-2 post hoc subgroup analysis evaluating outcomes of patients enrolled in Japan.

Methods

In FRESCO-2, patients had previously received all standard chemotherapies, anti-VEGF and anti-EGFR therapies if indicated, and had progressed on, or were intolerant to trifluridine-tipiracil and/or regorafenib. Patients were randomized 2:1 to receive fruquintinib 5 mg or matching placebo by mouth once daily on days 1–21 in 28-day cycles, plus BSC. The primary endpoint was OS; secondary endpoints included progression-free survival (PFS) and safety.

Results

Of the 56 patients enrolled in Japan, 40 (71.4%) and 16 (28.6%) were randomized to fruquintinib and placebo, respectively. OS was improved with fruquintinib versus placebo (median 6.9 vs. 5.6 months; hazard ratio [HR], 0.42; 95% confidence interval [CI] 0.19 − 0.92). PFS was also improved with fruquintinib versus placebo (median 3.6 vs. 1.8 months; HR, 0.27; 95% CI 0.13 − 0.56). The incidence of grade ≥ 3 treatment-emergent adverse events (TEAEs) with fruquintinib versus placebo was 71.8% versus 29.4%; the most common grade ≥ 3 TEAEs with fruquintinib were hypertension (23.1%) and palmar-plantar erythrodysesthesia (17.9%).

Conclusions

Fruquintinib improved OS and PFS versus placebo in FRESCO-2 patients enrolled in Japan and demonstrated a manageable safety profile. Results from the Japan subgroup were consistent with the global FRESCO-2 population, thus supporting fruquintinib as a novel treatment option for patients in Japan with refractory mCRC. Clinical trial details ClinicalTrials.gov; NCT04322539.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsBenzofuransQuinazolinesHumansFemaleMaleMiddle AgedAgedJapanAdultAged, 80 and overProgression-Free SurvivalDouble-Blind MethodNeoplasm MetastasisDrug Resistance, Neoplasm

Stichwörter der Autor:innen

FruquintinibJapan subgroup analysisMetastatic colorectal cancerVEGFR inhibitor

Substanzen

BenzofuransQuinazolinesHMPL-013

Autor:innen und Institutionen

  • Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. dkotani@east.ncc.go.jp.
  • Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Department of Clinical Oncology, Aichi Cancer Center, Nagoya, Japan.
  • Department of Clinical Oncology, St Marianna University School of Medicine, Kanagawa, Japan.
  • Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.

Förderung

  • HUTCHMED

Zitieren

APA

Kotani, D., Yoshino, T., Masuishi, T., Sunakawa, Y., Takashima, A., Yamazaki, K., Kawakami, H., Nishina, T., Komatsu, Y., Esaki, T., Eng, C., Ukrainskyj, S., Pallai, R., Nanda, S., Yang, Z., Schelman, W., Kania, M., & Satoh, T. (2025). Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02852-9

Vancouver

Kotani D, Yoshino T, Masuishi T, Sunakawa Y, Takashima A, Yamazaki K, et al. Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-025-02852-9

BibTeX
@article{Kotani2025,
  author = {Kotani, Daisuke and Yoshino, Takayuki and Masuishi, Toshiki and Sunakawa, Yu and Takashima, Atsuo and Yamazaki, Kentaro and Kawakami, Hisato and Nishina, Tomohiro and Komatsu, Yoshito and Esaki, Taito and Eng, Cathy and Ukrainskyj, Stacey and Pallai, Rajash and Nanda, Shivani and Yang, Zhao and Schelman, William and Kania, Marek and Satoh, Taroh},
  title = {Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan},
  journal = {International Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1007/s10147-025-02852-9}
}
Kostenlos starten →